SCHEMBL3683483

SCHEMBL3683483

Nc1cc2[nH]c(=O)c(=O)[nH]c2c2cccc(S(N)(=O)=O)c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
ALDH1A1 P00352 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
KDM4E B2RXH2 1/20 0.67
MEN1 O00255 1/20 0.67
GRM6 O15303 1/20 0.67
GLA P06280 1/20 0.67
MAPT P10636 1/20 0.67
THRB P10828 1/20 0.67
HPGD P15428 1/20 0.67
ALOX15 P16050 1/20 0.67
CYP2C19 P33261 1/20 0.67
GRIK1 P39086 1/20 0.67
GRIA1 P42261 1/20 0.67
GRIA2 P42262 1/20 0.67
GRIA3 P42263 1/20 0.67
RECQL P46063 1/20 0.67
GRIA4 P48058 1/20 0.67
GRIK2 Q13002 1/20 0.67
GRIK3 Q13003 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nbqx SCHEMBL29356960 0.80 GRIA1 (1.00) KMT2AALDH1A1TDP1KDM4EMEN1
Nbqx SCHEMBL120375 0.80 GRIA1 (1.00) KMT2AALDH1A1TDP1KDM4EMEN1
Nbqx SCHEMBL2487669 0.79 GRIA1 (0.98) KMT2AALDH1A1TDP1KDM4EMEN1
Nbqx SCHEMBL3681836 0.79 GRIA1 (0.98) KMT2AALDH1A1TDP1KDM4EMEN1
SCHEMBL9747625 0.78 KMT2A (0.56) KMT2AALDH1A1TDP1KDM4EMEN1
SCHEMBL16513096 0.76 KMT2A (0.58) KMT2AALDH1A1TDP1KDM4EMEN1
SCHEMBL3683241 0.72 MAPT (0.45) KMT2AALDH1A1TDP1KDM4EMEN1
Hydrochloric Acid SCHEMBL3683097 0.71 MAPT (0.44) KMT2AALDH1A1TDP1KDM4EMEN1
SCHEMBL6686773 0.71 PARP1 (0.54) KMT2AALDH1A1TDP1KDM4EMEN1
SCHEMBL3678511 0.69 GRIA1 (0.82) KMT2AALDH1A1TDP1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8603980-B2 Glutamate receptor antagonists and methods of use THE JOHNS HOPKINS UNIVERSITY (US) 2013-12-10 US disclosed
US-20100196354-A1 GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE THE JOHNS HOPKINS UNIVERSITY (US) 2010-08-05 US disclosed
EP-2150248-A2 GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE The Johns Hopkins University (US) 2010-02-10 EP disclosed
WO-2008088820-A2 GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE THE JOHNS HOPKINS UNIVERSITY (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196354-A1 GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE GRM5, GRM1, GRM3 KMT2A 1270/4885ALDH1A1 1900/4885TDP1 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.